GlobeNewswire

Segment Launches New End-User Privacy Tools that Streamline and Simplify GDPR Compliance Across Segment and Supported Partners

Dela

The Leading Customer Data Platform Helps Companies Manage User Deletion Requests; Automatically Forwards Requests to Supported Integrations

SAN FRANCISCO, April 24, 2018 (GLOBE NEWSWIRE) -- Segment, the customer data platform, today announced the availability of new product features that will help brands achieve compliance with the European Union's General Data Protection Regulation (GDPR), which takes effect May 25, 2018. Using either a simple user interface or an API, Segment customers will be able to manage user deletion and suppression requests, as well as automatically forward them to supported Segment integrations such as Amplitude, Braze (formerly Appboy), Intercom and Iterable. With these new features, Segment helps its customers meet key end-user rights requests under the GDPR.

"We welcome the GDPR because it sets a new standard for privacy rights, requiring businesses to be more transparent about how they use their customers' personal data," said Peter Reinhardt, co-founder and CEO of Segment. "Segment has always been committed to building a customer data platform that is respectful of user privacy and powered by first-party data. We are dedicated not only to helping our customers achieve GDPR compliance, but also to fostering a partner ecosystem that is privacy-conscious and prioritizes the rights of the individual."

Under the GDPR, consumer rights are strengthened and expanded, and end-user rights requests are likely to increase given the recent widespread interest in consumer privacy. While the GDPR will raise the bar for protecting end-users' rights and privacy, it presents a complex technological challenge for most companies - evidenced by a Gartner estimate that more than 50 percent of companies affected by the GDPR will not be in full compliance by the time the law goes into effect.

Streamline Compliance with GDPR Rights Requests

With Segment, brands will be able to operationalize GDPR rights requests through a new, simple user interface or a new API. Specifically, companies will be able to:

  • Issue deletion requests to delete a specified user's data from Segment. Data will be deleted where it is stored on the Segment platform.
  • Issue deletion requests to delete user data from supported integrations. Issuing a delete call will also delete a user's data from Amazon Redshift, Amazon S3, Google BigQuery and Postgres.
  • Forward user deletion requests to supported integrations. Segment automatically forwards deletion requests to supported integrations, like Amplitude, Braze (formerly Appboy), Intercom and Iterable.
  • Suppress data collection for specific users. Add users to a suppression list to restrict user data from being sent to Segment and supported integrations.
  • Monitor deletion and suppression status from a user interface. To help with monitoring and auditing rights requests, all user deletion and suppression requests will be documented within Segment.

In addition, Segment's existing functionality already supports:

  • Honoring the rights to access and portability. Segment's raw data integrations and warehouses enable companies to compile a complete picture of all data sent to Segment about a user and share it with them in a structured format.
  • Rectifying user data. With just a single API call, companies can create or update a user's data inside of Segment and across a company's connected integrations, ensuring a user's data is always up-to-date.

"Amplitude and Segment share a similar mission. We want to help companies build great products, engage their customers and grow their business," said Spenser Skates, CEO of Amplitude. "We are delighted to announce that we have further strengthened this partnership. We are working together to prioritize and simplify user privacy for all."

"Braze (formerly Appboy) is committed to ongoing compliance with the GDPR, serving as good stewards of our clients' data, and promoting seamless data connections between our partners," said Bill Magnuson, CEO and co-founder of Braze (formerly Appboy). "Working in partnership with Segment to streamline and simplify end-user requests helps us to accomplish these goals, while also supporting brands as they work toward compliance with the GDPR."

About Segment
Segment is the infrastructure for your customer data. Use one API to unlock 200+ tools for every team in your company. With Segment, developers can stop building tedious and expensive one-off data integrations while business users can compute important traits about each customer and push this data to their favorite apps for analytics and personalization. Segment is trusted by thousands of companies including Gap Inc., New Relic, Instacart, Intuit, and Time. For more information visit https://segment. com.

Danielle Stickler
segment@bateman-group.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Segment via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum